Side-Chain Homologs of Δ9-THC, Δ8-THC, and HHC Reveal Pathway Bias at CB1R and CB2R Cannabinoid Receptors.
Oleh Durydivka, Ondřej Florián, Petr Palivec, Monika Mrňavá, Petra Cihlářová, Martin Kuchař
Molecular Neurobiology August 20, 2026 DOI: 10.1007/s12035-026-06145-8 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | In vitro pharmacological study Peer reviewed |
|---|---|
| Population | HEK293 cells expressing CB1R or CB2R cannabinoid receptors |
| Interventions | Δ9-THC Δ8-THC (9R)-HHC |
| Measures | BRET-based platform measuring Gi1, Gi2, Gi3, GoA, GoB, Gz activation and β-arrestin1/β-arrestin2 recruitment |
| Topics | Cannabis |
| Keywords | Arrestins Cannabinoid receptors G protein-coupled receptors Signal transduction Structure-activity relationship |
| Key points | Side-chain length was the dominant determinant of signaling efficiency for THC and HHC homologs, with C4-C8 acting as high-efficacy Gi/o agonists and partial β-arrestin agonists, and potency peaking at C7-C8. C3 homologs showed minimal agonism and instead acted as CB1R antagonists. 9R-HHC homologs were consistently more potent than 9S-HHC homologs, while Δ9/Δ8 isomerism and hydrogenation effects were context-dependent. |
Abstract
Minor cannabinoids and semisynthetic cannabis constituents, such as derivatives of tetrahydrocannabinol (THC) and hexahydrocannabinol (HHC), are increasingly encountered in consumer products, yet their signaling profiles at cannabinoid receptors remain incompletely characterized. Here, we describe how structural modifications of THC and HHC, including variations in alkyl side-chain length (C3-C8), double-bond position (Δ9 vs Δ8), and HHC stereochemistry (9R vs 9S), shape signaling at CB1R and CB2R cannabinoid receptors. Using a BRET-based platform in HEK293 cells, we determined pathway-specific potency, efficacy, receptor selectivity, and signaling bias in isoform-specific inhibitory G protein activation (Gi1, Gi2, Gi3, GoA, GoB, Gz) and β-arrestin recruitment (β-arr1, β-arr2) of a panel of Δ9-THC, Δ8-THC, (9R)-HHC, and (9S)-HHC side-chain homologs. C3 side-chain ligands were additionally evaluated in antagonist mode. Across both receptors, C4-C8 homologs behaved as high-efficacy agonists in Gi/o pathways while remaining partial agonists in β-arrestin recruitment. Side-chain elongation was the dominant determinant of signaling efficiency, producing progressive potency gains that peaked for C7-C8 homologs. Δ9/Δ8 isomerism and hydrogenation effects were context-dependent, while HHC epimerism imposed a consistent separation, with 9R-HHC homologs exhibiting higher potency than matched 9S-HHC homologs. In contrast, C3 homologs exhibited minimal agonism and instead displayed functional CB1R antagonism, with partial inhibition of G protein pathways and near-maximal inhibition of β-arrestin recruitment. These findings provide quantitative, pathway-resolved benchmarks for how closely related cannabinoid scaffolds signal through receptor- and transducer-specific pathways and indicate structural features that may be leveraged to tune CB1R/CB2R selectivity and G protein versus β-arrestin engagement.
Comparable studies
Other preclinical and animal studies on cannabis, most cited first.
Citations in the library
Cites 11
- Hexahydrocannabinol (HHC) and Δ9-tetrahydrocannabinol (Δ9-THC) driven activation of cannabinoid receptor 1 results in biased intracellular signaling Scientific Reports April 22, 2024
- Structural basis of THC analog activity at the Cannabinoid 1 receptor Nature Communications January 8, 2025
- Review of delta‐8‐tetrahydrocannabinol (Δ8‐THC): Comparative pharmacology with Δ9‐THC British Journal of Pharmacology August 1, 2022
- In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa Scientific Reports November 23, 2020
- Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ9-Tetrahydrocannabinol and JWH-018. Journal of Pharmacology and Experimental Therapeutics May 2019
and 6 more in the library